BREDA, The Netherlands and GHENT, Belgium, April 7, 2014 /PRNewswire/ --
New findings to be presented at the American Association for Cancer Research annual meeting
arGEN-X, a clinical stage human therapeutic antibody company, will present data on how its SIMPLE Antibody™ platform has identified four 'hotspots' on the MET protein that are suitable for therapeutic antibody targeting. Encoded by the oncogene c-Met, MET signalling is involved in cancer proliferation and metastasis and is activated by hepatocyte growth factor (HGF) in multiple cancers.
Help employers find you! Check out all the jobs and post your resume.
